CCN3 and chronic myelogenous leukemia, BCR-ABL1 positive: Several of these biological properties are shared by CCN3 whose expression was reported to be increased in malignant tumors, to interfere with adipocitic differentiation, and to be involved in the tumorigenic phenotype of CML.